The chapter addresses fatal incidents: patients who received experimental substances and died during or shortly after their administration. The focus is less on the cause of death than on how Kuhn dealt with these deaths, what he attributed them to, and how he informed about them. This is contrasted with the reactions of other players: the pharmaceutical companies, other doctors and hospitals. The individual cases analysed are from four different decades, so the chapter also looks at the changing ways of dealing with the death of test patients over time.